KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
2.170
-0.260 (-10.70%)
At close: May 26, 2026, 4:00 PM EDT
2.160
-0.010 (-0.46%)
After-hours: May 26, 2026, 7:59 PM EDT
KALA BIO Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
40.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.89M | -7.35M | -65.37% |
| Dec 31, 2021 | 11.24M | 4.88M | 76.67% |
| Dec 31, 2020 | 6.36M | 288.00K | 4.74% |
| Dec 31, 2019 | 6.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 45.00K | -410.00K | -90.11% |
| Dec 31, 2014 | 455.00K | 405.00K | 810.00% |
| Dec 31, 2013 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gossamer Bio | 55.54M |
| Xilio Therapeutics | 53.48M |
| Metagenomi Therapeutics | 22.33M |
| Plus Therapeutics | 5.18M |
| Nutriband | 2.04M |
| Mereo BioPharma Group | 500.00K |
| aTyr Pharma | 190.00K |
KALA News
- 11 days ago - KALA BIO Quarterly report: Q1 2026 - Filings
- 14 days ago - Kala Bio falls -21.7% - TheFly
- 19 days ago - Kala Bio files $350M mixed securities shelf - TheFly
- 19 days ago - Kala Bio announces reverse stock split - TheFly
- 19 days ago - KALA BIO Announces Reverse Stock Split - GlobeNewsWire
- 19 days ago - KALA BIO Registration statement: Registration filing - Filings
- 5 weeks ago - Kala Bio ‘celebrates’ U.S. Executive Order for psychedelic medicine - TheFly
- 5 weeks ago - Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine - GlobeNewsWire